161results about "Chemokines" patented technology

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

Provided herein are modified NK-92 cells comprising a nucleic acid encoding C-C chemokine receptor type 7 (CCR7) operably linked to a promoter. Optionally, the cells further comprise a nucleic acid encoding C-C motif ligand 21 (CCL21), a nucleic acid encoding C-C motif ligand 19 (CCL19) or a combination thereof. Also provided are compositions and kits comprising the modified NK-92 cells. Provided are methods of making the modified cells and methods of treating cancer using the cells.

The disclosure relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and / or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved.

The present disclosure generally relates to a viral vector carrying a synthetic cancer antigen and a chemokine. Also provided herein are compositions and uses of the viral vector for delivering, such as tagging, a tumor with the synthetic cancer antigen.

The present invention provides a pluripotent stem cell expressing the following (a) and (b): (a) an exogenous gene encoding CC chemokine receptor 2 type B(CCR2B) (b) an exogenous gene encoding CC chemokine ligand 19 (CCL19), or an NK cell derived from the pluripotent stem cell or a progenitor cell thereof.

Provided herein are macromolecules that conditionally induce a cellular effector function (e.g., a biological or therapeutic activity) based on the presence of a disease signature ligand, compositions comprising the same, and methods of using the same.

To provide: in the field of oncolytic viruses, in particular a recombinant rhabdovirus, such as vesicular stomatitis virus encoding a CCL21 protein in its genome; and the use of the recombinant virus in treatment of cancer, and also methods for producing such viruses.SOLUTION: The present invention provides, in the field of oncolytic viruses, in particular a recombinant rhabdovirus, such as vesicular stomatitis virus encoding a CCL21 protein in its genome. The invention further provides the use of the recombinant virus in treatment of cancer, and also methods for producing such viruses.SELECTED DRAWING: None

This disclosure provides, inter alia, genetically engineered cells having an artificial protospacer-adjacent motif (PAM) introduced via a CRISPR / Cas-mediated gene editing, and optionally, one or more modifications in a target gene. The disclosure also provides methods and compositions, including gRNAs, that can be used to make such modifications.

A chemokine mixture suitable for modulating an immune response, comprising a first chemokine, or an agonist or antagonist mutant thereof, suitable for binding to CCR4, and a second chemokine, or an agonist or antagonist mutant thereof, suitable for binding to CCR5 and / or CCR6.

Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and / or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and / or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.

The present invention relates to novel peptides, compositions and kits comprising said peptides, for use as active ingredients for preventing or treating pain in a subject in need thereof. In vitro or ex vivo methods for modulating the expression of these peptides are also described herein.

The specification relates to a method of manufacturing a diabetic foot patient-specific skin regeneration sheet, and a diabetic foot patient-specific skin regeneration sheet.

The present disclosure relates to CXCR3 ligands having CXCR3-expressing-cell migration-inducing activity, and specifically to amino acid modifications and amino acid sequences that are important for CXCR3-expressing-cell migration-inducing activity.

The present invention relates to immune cells expressing IL-7 (interleukin-7), CCL19 (CC Motif Chemokine Ligand 19), or a combination thereof, and compositions containing the same as active ingredients for the prevention or treatment of cancer or infectious diseases. The present invention provides a multifaceted and synergistic therapeutic effect through the complementary immune response between the patient's endogenous T cells and the infused natural killer cells by injecting only a therapeutically effective amount of immune cells other than T cells. Furthermore, the present invention also provides a significantly improved therapeutic effect when administering T cells and immune cells other than T cells, specifically natural killer cells, by allowing these different cell groups to act more intensively at the lesion site.

The invention relates to the field of biological medicine, in particular to a medicine for treating HPV infection related diseases. The invention provides antigen combinations, fusion proteins and encoding nucleic acids. The materials are used for preparing self-replicating RNA vaccines for treating cervical HPV persistent infection, intraepithelial neoplasia induced by the cervical HPV persistent infection and cervical cancer, and indications can be expanded to HPV long-term infected people. Therefore, not only can virus host cells be removed to treat long-term infection, but also precancerous lesions and cervical cancer can be treated more effectively.

The present invention relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and / or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved. The key point of the present invention is that a T2 sequence added to an antigen can enhance an immune response.

The invention relates to methods of treating a tumor in a subject by administering to the subject the following active agents: (a) interleukin- 12 (IL-12), a nucleotide expressing IL-12, or combinations thereof; and (b) c-c motif chemokine ligand 3 (CCL3), a nucleotide expressing CCL3, or combinations thereof. The invention also relates to therapeutic compositions that include the following active agents; (a) IL-12, a nucleotide expressing IL-12, or combinations thereof; and (b) CCL3, a nucleotide expressing CCL3, or combinations thereof.

To provide cleavable activators of CXCR3 and methods of use.SOLUTION: Disclosed is a recombinant C-X-C motif chemokine ligand (CXCL) peptide modified to introduce a cleavage site for a protease (e.g., a protease that is activated during an inflammation response). The CXCL peptide has an ability to activate CXCR3 until the protease cleaves the peptide. The proteolytic cleavage of the CXCL peptide minimizes pro-inflammatory response and inhibits the development of fibrosis. The CXCL may be CXCL10, CXCL4, CXCL9 or CXCL11.SELECTED DRAWING: None

The present disclosure provides immunomodulatory fusion proteins-metal hydroxide complexes comprising an immunomodulatory domain adsorbed to a metal hydroxide via ligand exchange. The disclosure also features compositions and methods of using the same, for example, to treat cancer.

This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) are provided.

This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac evert as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) are provided.

Nucleic acids encoding recombinant fusion proteins directed to calreticulin are described, as well as pharmaceutical compositions comprising such nucleic acids and therapeutic methods using such nucleic acids and pharmaceutical compositions, such as for treating cancer.

The present invention discloses a CXCL-BPI fusion protein that can be used for treating Gram-negative bacterial infections, a coding nucleic acid thereof, a method for expressing and preparing the same, and a use thereof in the manufacture of a pharmaceutical composition for treating Gram-negative bacterial infections. The CXCL-BPI fusion protein comprises a human ELR+CXC chemokine and a bioactive fragment of N-terminal domain of human BPI, and has the dual functions of both ELR+CXC chemokine and BPI, with ability of binding to LPS and directly killing Gram-negative bacteria, and also inducing chemotaxis and promoting phagocytes to target, bind to and phagocytize Gram-negative bacteria. The mechanism of action of the fusion protein can overcome Gram-negative bacterial drug resistance.

To provide a vaccinia virus having a therapeutic gene introduced therein as a foreign gene, and a therapeutic composition including the vaccinia virus.SOLUTION: A vaccinia virus contains, as a foreign gene, at least one immunoregulatory gene.SELECTED DRAWING: None

The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.

Described herein are compositions and methods for regulating the expression of effector molecules using engineered CCL3 promoters.Also described are immunoresponsive cells comprising the same.Furthermore, wherein the engineered CCL3 promoter comprises a truncation of at least one nucleotide motif, wherein the truncation increases the inducibility of the engineered CCL3 promoter in the presence of an immune cell activation signal compared to the inducibility of the wild-type CCL3 promoter in the presence of the same immune cell activation signal.

The present invention provides a hypoxia-triggered artificial transcription factor (HATF), and further provides a hypoxia-triggered transcription control system. The transcription control system comprises a nucleic acid sequence encoding the HATF, and a recognition element (RE). The hypoxia-triggered transcription control system comprises two sets of transcription control units linked upstream and downstream, wherein the upstream transcription control unit comprises a hypoxia-triggered transcription reaction element for controlling the HATF and a nucleic acid sequence encoding the HATF, and the downstream transcription control unit comprises an RE and a gene of interest. Co-regulation by the artificial transcription factor HATF and the recognition element RE can increase the expression of the gene of interest by a factor of one hundred.

Disclosed herein are programmable bacteria for tumor-targeted immunotherapeutic delivery. In certain embodiments, the programmable bacteria comprise at least one synchronized lysis circuit contained in a single operon which are capable of being further engineered to cyclically produce anti-cancer therapeutic agents including but not limited to nanobodies against immune checkpoint inhibitors and over-expressed markers in cancers, toxins, tumor antigens, cytokines, and chemokines. In some embodiments, the programmable bacteria comprise at least one synchronized lysis circuit contained in a single operon and at least one plasmid producing a therapeutic agent, i.e., at least one plasmid comprising a nucleic acid sequence which encodes a therapeutic agent. The disclosure also provides methods of curing and treating cancer using the programmable bacteria.